| Code | Description | Claims | Beneficiaries | Total Paid |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
29,477 |
25,063 |
$4.76M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
18,439 |
15,099 |
$2.72M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
10,142 |
7,674 |
$2.69M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
5,423 |
4,741 |
$1.02M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
17,847 |
5,251 |
$884K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
11,049 |
8,532 |
$811K |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,479 |
3,802 |
$728K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,998 |
4,552 |
$712K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
3,579 |
2,989 |
$441K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,674 |
3,070 |
$420K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,097 |
1,846 |
$351K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
2,622 |
2,025 |
$267K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
5,037 |
4,086 |
$189K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,216 |
2,064 |
$186K |
| 20610 |
|
1,340 |
1,066 |
$181K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
621 |
556 |
$176K |
| 97161 |
|
1,916 |
1,787 |
$167K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
693 |
616 |
$139K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,017 |
713 |
$125K |
| G0378 |
Hospital observation service, per hour |
1,016 |
814 |
$118K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
4,685 |
2,084 |
$105K |
| 80053 |
Comprehensive metabolic panel |
27,096 |
21,152 |
$102K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
1,340 |
1,208 |
$95K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
989 |
930 |
$92K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
4,342 |
3,913 |
$90K |
| 71046 |
Radiologic examination, chest; 2 views |
5,811 |
5,113 |
$90K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,149 |
1,611 |
$89K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,402 |
2,311 |
$89K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
454 |
427 |
$77K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
227 |
220 |
$74K |
| 76642 |
|
519 |
500 |
$61K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
264 |
248 |
$51K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
69 |
65 |
$51K |
| 93971 |
|
422 |
374 |
$45K |
| 73030 |
|
2,267 |
1,922 |
$42K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
685 |
671 |
$38K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
14,985 |
12,112 |
$35K |
| 97162 |
|
210 |
199 |
$32K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,372 |
1,184 |
$32K |
| 73630 |
|
1,793 |
1,538 |
$29K |
| 72100 |
|
1,197 |
1,115 |
$29K |
| 73610 |
|
1,706 |
1,443 |
$29K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
30,352 |
23,081 |
$28K |
| 71271 |
|
210 |
206 |
$23K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
42 |
38 |
$23K |
| 73130 |
|
1,189 |
1,029 |
$22K |
| 71045 |
Radiologic examination, chest; single view |
10,662 |
8,743 |
$21K |
| 73560 |
|
1,218 |
1,032 |
$20K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
11,426 |
9,190 |
$20K |
| 81025 |
|
3,394 |
3,011 |
$19K |
| 73564 |
|
576 |
521 |
$19K |
| 73562 |
|
1,306 |
1,157 |
$19K |
| 93017 |
|
107 |
97 |
$18K |
| 73110 |
|
885 |
707 |
$17K |
| 72040 |
|
551 |
520 |
$17K |
| 71250 |
|
309 |
269 |
$16K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
80 |
76 |
$16K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,902 |
3,063 |
$16K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
27 |
24 |
$16K |
| 87040 |
|
2,851 |
1,295 |
$15K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
803 |
768 |
$14K |
| 36415 |
Collection of venous blood by venipuncture |
12,250 |
10,255 |
$11K |
| 83880 |
|
1,817 |
1,460 |
$11K |
| 84484 |
|
11,255 |
7,194 |
$10K |
| 73502 |
|
497 |
412 |
$8K |
| J3490 |
Unclassified drugs |
9,817 |
4,796 |
$7K |
| 90715 |
|
341 |
321 |
$7K |
| 74018 |
|
426 |
379 |
$7K |
| 97750 |
|
341 |
314 |
$7K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
26 |
25 |
$6K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,008 |
1,812 |
$5K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
7,534 |
6,066 |
$5K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
2,836 |
2,472 |
$5K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
61 |
52 |
$5K |
| 12001 |
|
26 |
24 |
$5K |
| 85379 |
|
1,124 |
985 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,807 |
3,506 |
$5K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
7,028 |
5,665 |
$4K |
| 76830 |
Ultrasound, transvaginal |
29 |
28 |
$4K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
140 |
100 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
6,902 |
5,706 |
$3K |
| 76775 |
|
41 |
38 |
$3K |
| 20550 |
|
15 |
12 |
$3K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,828 |
3,050 |
$3K |
| 70491 |
|
16 |
14 |
$3K |
| 86756 |
|
538 |
522 |
$3K |
| 72141 |
|
14 |
13 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
7,634 |
6,083 |
$3K |
| 73080 |
|
96 |
82 |
$2K |
| 83735 |
|
5,250 |
4,065 |
$2K |
| 70486 |
|
25 |
24 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
855 |
774 |
$2K |
| 00811 |
|
159 |
145 |
$2K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,158 |
1,443 |
$2K |
| 97116 |
|
79 |
36 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
528 |
443 |
$2K |
| 83605 |
|
3,474 |
2,479 |
$2K |
| 81001 |
|
14,314 |
11,758 |
$2K |
| 77080 |
|
39 |
36 |
$2K |
| 80047 |
|
576 |
504 |
$2K |
| 86885 |
|
757 |
656 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
11,312 |
7,215 |
$1K |
| 76536 |
|
12 |
12 |
$1K |
| 85610 |
|
3,696 |
2,885 |
$1K |
| 51798 |
|
448 |
395 |
$1K |
| 80061 |
Lipid panel |
541 |
514 |
$1K |
| 80143 |
|
166 |
148 |
$1K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
13 |
13 |
$1K |
| 87081 |
|
2,546 |
2,331 |
$1K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,904 |
1,456 |
$1K |
| 72110 |
|
102 |
92 |
$1K |
| 86900 |
|
998 |
846 |
$1K |
| 73590 |
|
83 |
66 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,659 |
1,391 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,906 |
1,403 |
$995.99 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
10,634 |
4,770 |
$967.71 |
| 82947 |
|
4,162 |
2,476 |
$893.31 |
| J3480 |
Injection, potassium chloride, per 2 meq |
53 |
41 |
$666.80 |
| 96367 |
|
38 |
26 |
$666.54 |
| J2704 |
Injection, propofol, 10 mg |
7,045 |
3,817 |
$651.51 |
| 86901 |
|
998 |
846 |
$646.29 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
98 |
97 |
$642.52 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
26 |
12 |
$616.53 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
594 |
460 |
$586.33 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
672 |
592 |
$573.33 |
| 94060 |
|
17 |
12 |
$565.96 |
| J2274 |
Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg |
107 |
75 |
$552.62 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
62 |
51 |
$531.60 |
| 86140 |
|
134 |
111 |
$520.92 |
| 36430 |
|
22 |
12 |
$517.90 |
| 84703 |
|
2,495 |
2,253 |
$498.51 |
| 84145 |
|
239 |
182 |
$468.70 |
| 82077 |
|
2,584 |
2,139 |
$454.76 |
| 80179 |
|
110 |
105 |
$453.39 |
| 82565 |
|
741 |
688 |
$448.11 |
| 87077 |
|
2,820 |
2,097 |
$407.00 |
| 83690 |
|
6,221 |
5,112 |
$404.26 |
| 73140 |
|
40 |
36 |
$368.50 |
| 85652 |
|
238 |
176 |
$332.96 |
| 85730 |
|
1,299 |
1,143 |
$309.89 |
| 73552 |
|
51 |
49 |
$283.88 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,908 |
2,441 |
$251.28 |
| 85014 |
|
1,293 |
1,024 |
$251.15 |
| 73501 |
|
15 |
12 |
$251.02 |
| 80069 |
|
111 |
88 |
$239.80 |
| 87430 |
|
2,741 |
2,517 |
$228.51 |
| 87186 |
|
2,552 |
1,883 |
$217.87 |
| 94727 |
|
17 |
12 |
$213.36 |
| 94729 |
|
17 |
12 |
$213.36 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,442 |
1,087 |
$194.67 |
| 73090 |
|
14 |
12 |
$168.75 |
| J2060 |
Injection, lorazepam, 2 mg |
819 |
656 |
$151.95 |
| 81002 |
|
941 |
792 |
$140.35 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,060 |
1,758 |
$139.27 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
1,705 |
1,208 |
$125.40 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
1,095 |
920 |
$103.34 |
| 81003 |
|
1,323 |
1,178 |
$80.07 |
| 84439 |
|
46 |
46 |
$76.85 |
| 84702 |
|
30 |
25 |
$63.47 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
766 |
673 |
$60.67 |
| A9150 |
Non-prescription drugs |
24,616 |
10,799 |
$60.04 |
| 71101 |
|
13 |
12 |
$59.27 |
| 36592 |
|
300 |
231 |
$59.08 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
822 |
590 |
$53.11 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
613 |
540 |
$49.74 |
| 82607 |
|
17 |
12 |
$48.42 |
| 85018 |
|
77 |
38 |
$33.33 |
| 00731 |
|
145 |
141 |
$25.16 |
| 87205 |
|
93 |
76 |
$17.20 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
357 |
229 |
$16.75 |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
235 |
170 |
$12.87 |
| J1815 |
Injection, insulin, per 5 units |
136 |
59 |
$12.21 |
| 82803 |
|
126 |
100 |
$12.02 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
539 |
434 |
$11.27 |
| 82550 |
|
80 |
65 |
$10.66 |
| 96376 |
|
1,988 |
1,497 |
$8.97 |
| 87070 |
|
14 |
13 |
$8.60 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
281 |
230 |
$8.37 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
109 |
102 |
$6.80 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
77 |
39 |
$5.80 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
38 |
15 |
$4.56 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
46 |
43 |
$2.40 |
| J1940 |
Injection, furosemide, up to 20 mg |
71 |
53 |
$2.20 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
15 |
15 |
$1.88 |
| A9270 |
Non-covered item or service |
5,141 |
1,304 |
$0.06 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
28 |
24 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
30 |
28 |
$0.00 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
97 |
50 |
$0.00 |
| A4351 |
Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each |
379 |
274 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
106 |
99 |
$0.00 |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
45 |
40 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
62 |
51 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
133 |
121 |
$0.00 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
3,427 |
2,749 |
$0.00 |
| 87210 |
|
23 |
13 |
$0.00 |
| 00812 |
|
150 |
143 |
$0.00 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
739 |
622 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
36 |
24 |
$0.00 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
16 |
13 |
$0.00 |
| A6402 |
Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
47 |
36 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
18 |
13 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
23 |
14 |
$0.00 |
| 84100 |
|
14 |
12 |
$0.00 |